Firm halting sales of dietary supplement Anatabloc

August 12, 2014 by Michael Felberbaum

The dietary supplement maker at the center of a federal trial of former Virginia Gov. Bob McDonnell and his wife says it's halting sales of its product called Anatabloc.

Rock Creek Pharmaceuticals Inc. said Monday it is voluntarily stopping sales while it sorts out issues with the Food and Drug Administration.

Last year, the federal agency sent a warning letter to the company known as Star Scientific saying that its products contain a new dietary ingredient that requires approval before it can be marketed.

The agency also said the company's website had improperly promoted Anatabloc as a drug by suggesting it can be used to treat various diseases.

The McDonnells are charged with accepting gifts and loans from Star Scientific's former CEO in exchange for promoting his products.

Explore further: Virginia tobacco maker seeks new FDA designation

Related Stories

Virginia tobacco maker seeks new FDA designation

January 4, 2011

(AP) -- Tobacco maker Star Scientific Inc. says it has developed a moist smokeless tobacco with lower levels of cancer-causing chemicals than any other tobacco product now on the market.

US watchdog warns on fitness stimulant

April 27, 2012

The US Food and Drug Administration on Friday questioned the safety of DMAA, a stimulant used in dietary supplements, alleging that marketers were illegally selling the chemical.

FDA seizes illegal dietary supplements in Florida

February 14, 2013

(AP)—The Food and Drug Administration says U.S. marshals have seized illegal dietary supplements from a Florida company because some may contain a dangerous pharmaceutical ingredient.

FDA warns of steroids in vitamin B supplement

July 27, 2013

(AP)—The Food and Drug Administration is warning consumers to avoid a vitamin B dietary supplement from Healthy Life Chemistry by Purity First because it contains two potentially dangerous anabolic steroids.

Orbactiv approved for drug-resistant skin infections

August 7, 2014

(HealthDay)—The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.